The VCaP cell line was established in 1990, derived from a spinal metastasis of a 69-year-old male prostate cancer patient. The patient had previously undergone various treatments, including hormonal therapy, which gives this cell line a unique "history." It retains androgen receptor (AR) functionality, with AR gene amplification observed, and expresses prostate-specific antigen (PSA). These characteristics make VCaP an ideal model for studying the molecular mechanisms of androgen-dependent prostate cancer, drug development, and responses to hormonal therapy.

Cell Name: Human Prostate Cancer Cell Line
Cell Synonyms: VCAP; Vcap; Vertebral Cancer of the Prostate
Catalogue No.: TCH-C370
Species: Human
Tissue Origin: Spinal Metastasis
Disease Characteristics: Prostate Cancer
Morphology: Epithelial-like
Growth Properties: Adherent Growth
Culture Medium: DMEM-H + 20% FBS (Fetal Bovine Serum) + 1% P/S
Passage Ratio: 1:2–1:3, with medium change every 2–3 days
Doubling Time: 72–84 hours
Culture Conditions: Atmosphere: 95% air + 5% CO₂; Temperature: 37°C
Freezing Conditions: 60% basal medium + 30% FBS + 10% DMSO, stored in liquid nitrogen
Recommendation: Use HyCyte® One-Step Freezing Solution (ready-to-use, serum-free, no programmed cooling required), Product ID: GUCP-R201
Quality Control: Negative for bacteria, fungi, and mycoplasma

Notes:

1. VCaP cells grow slowly. After passaging, the cells require 48 hours to adhere, and medium change should be performed after 48 hours.

2. If small, bright-edged cell clusters are observed, it indicates incomplete adhesion. Normal cell morphology shows clumped, aggregated growth.